Cara L McDermott1, David A Gruenewald2,3. 1. Cambia Palliative Care Center of Excellence, University of Washington School of Medicine, Seattle, WA, USA. 2. Geriatrics and Extended Care Service, VA Puget Sound Health Care System, S-182-GEC, 1660 S. Columbian Way, Seattle, WA 98108, USA. 3. Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
Abstract
PURPOSE OF REVIEW: Agitation is common among older adults with dementia; its origin may be multi-factorial, and it is often difficult to treat. In this paper, we summarize current knowledge and offer considerations on pharmacologic management of behavioral and psychological symptoms of dementia (BPSD). RECENT FINDINGS: We reviewed human studies published from 2013 to 2018 evaluating pharmacologic management of BPSD manifestations including depressive symptoms, mania, psychosis, and other BPSD, as well as severe agitation without determination of underlying cause. After non-pharmacological management is exhausted, the choice of pharmacological options depends on patient comorbidities, specific BPSD presentation, and patient tolerance of medications. SUMMARY: Depending on manifestations of BPSD, low- to moderate-quality evidence supports the use of anti-depressants, anti-psychotics, or anti-epileptics in conjunction with cholinesterase inhibitors. The current evidence base needs to be augmented with future research that focuses on real-world medication use alongside head-to-head evaluation of medication effectiveness rather than comparison to placebo.
PURPOSE OF REVIEW: Agitation is common among older adults with dementia; its origin may be multi-factorial, and it is often difficult to treat. In this paper, we summarize current knowledge and offer considerations on pharmacologic management of behavioral and psychological symptoms of dementia (BPSD). RECENT FINDINGS: We reviewed human studies published from 2013 to 2018 evaluating pharmacologic management of BPSD manifestations including depressive symptoms, mania, psychosis, and other BPSD, as well as severe agitation without determination of underlying cause. After non-pharmacological management is exhausted, the choice of pharmacological options depends on patient comorbidities, specific BPSD presentation, and patient tolerance of medications. SUMMARY: Depending on manifestations of BPSD, low- to moderate-quality evidence supports the use of anti-depressants, anti-psychotics, or anti-epileptics in conjunction with cholinesterase inhibitors. The current evidence base needs to be augmented with future research that focuses on real-world medication use alongside head-to-head evaluation of medication effectiveness rather than comparison to placebo.
Authors: Pierre N Tariot; Lon S Schneider; Jeffrey Cummings; Ronald G Thomas; Rema Raman; Laura J Jakimovich; Rebekah Loy; Barbara Bartocci; Adam Fleisher; M Saleem Ismail; Anton Porsteinsson; Michael Weiner; Clifford R Jack; Leon Thal; Paul S Aisen Journal: Arch Gen Psychiatry Date: 2011-08
Authors: Walter A Rocca; Ronald C Petersen; David S Knopman; Liesi E Hebert; Denis A Evans; Kathleen S Hall; Sujuan Gao; Frederick W Unverzagt; Kenneth M Langa; Eric B Larson; Lon R White Journal: Alzheimers Dement Date: 2011-01 Impact factor: 21.566
Authors: I McKeith; T Del Ser; P Spano; M Emre; K Wesnes; R Anand; A Cicin-Sain; R Ferrara; R Spiegel Journal: Lancet Date: 2000-12-16 Impact factor: 79.321
Authors: Nicolaas I Bohnen; Daniel I Kaufer; Larry S Ivanco; Brian Lopresti; Robert A Koeppe; James G Davis; Chester A Mathis; Robert Y Moore; Steven T DeKosky Journal: Arch Neurol Date: 2003-12
Authors: Hiu Yi Wong; Huan Zhong; Mingqian Zhong; Xiaopu Zhou; Phillip Y C Chan; Timothy C Y Kwok; Kin Mok; John Hardy; Fanny C F Ip; Amy K Y Fu; Nancy Y Ip Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Melissa J Bailey-Taylor; Nicolas Poupore; Laurie Theriot Roley; Richard L Goodwin; Brooks Mcphail; Thomas I Nathaniel Journal: Brain Sci Date: 2022-01-26
Authors: Alok Joshi; Stephen Todd; David P Finn; Paula L McClean; KongFatt Wong-Lin Journal: BMC Med Inform Decis Mak Date: 2022-10-07 Impact factor: 3.298